

Journal of Visualized Experiments

Targeting gray rami communicantes, not sympathetic trunk, in selective chemical lumbar sympathectomy --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58894R2
Full Title:	Targeting gray rami communicantes, not sympathetic trunk, in selective chemical lumbar sympathectomy
Keywords:	chemical lumbar sympathectomy, complication, gray rami communicante, minimal invasive, ramicotomy, sympathetic trunk
Corresponding Author:	Long Zhang Peking University Third Hospital Beijing , Beijing CHINA
Corresponding Author's Institution:	Peking University Third Hospital
Corresponding Author E-Mail:	longzh2000@126.com
Order of Authors:	Wen-Hui Wang Long Zhang Guo-Xiang Dong Jun Zhao Xuan Li
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Beijing, China

TITLE:

Targeting Gray Rami Communicantes in Selective Chemical Lumbar Sympathectomy

AUTHORS & AFFILIATIONS:

Wen-Hui Wang¹, Long Zhang^{2,3}, Guo-Xiang Dong², Jun Zhao², Xuan Li^{2,3}

¹Department of Dermatology, Peking University Third Hospital, Beijing, China

²Department of Interventional Radiology and Vascular Surgery, Peking University Third Hospital, Beijing, China

³Wound Healing Center, Peking University Third Hospital, Beijing, China

Corresponding Author:

Long Zhang

longzh2000@126.com

Tel: 008613041210677

Email Addresses of Co-authors:

Wen-Hui Wang (wwh0608@126.com)

Guo-Xiang Dong (dongguoxiang18@126.com)

Jun Zhao (zhaojun2568@163.com)

Xuan Li (xuanli1030@sina.com)

KEYWORDS:

Chemical lumbar sympathectomy, complication, gray rami communicante, minimally invasive, ramicotomy, sympathetic trunk

SUMMARY:

We present a protocol for selective chemical lumbar sympathectomy (CLS), which inactivates only gray rami communicantes and not the sympathetic trunk. Selective CLS can help achieve therapeutic efficacy in vasodilation, sweat reduction, and pain relief that are comparable to conventional CLS, and serious complications, particularly ureteropelvic damages, can be reduced.

ABSTRACT:

Chemical lumbar sympathectomy (CLS) is a commonly used, minimally invasive procedure for the treatment of conditions including ischemic diseases of the lower extremities, hyperhidrosis, *etc.* It is commonly practiced to position the puncture needle tip in front of the anterior fascia of the psoas major muscle and inject the inactivating agent around the sympathetic trunk, which is defined as conventional CLS. Although relatively rare, ureteropelvic damage is the most frequently reported complication of conventional CLS and can cause serious harm to patients. We found that injecting the inactivating agent behind the anterior fascia, which only targets gray rami communicantes, helped achieve therapeutic efficacy in measures of vasodilation, sweat reduction, and pain relief comparable to conventional CLS, and serious complications were largely reduced. We define this procedure as selective CLS. Here, we present a protocol of selective CLS. The precise needle tract and accurate evaluation of the spreading of the contrast agent are critical to ensure that the drug is injected behind the anterior fascia of the psoas major

muscle. The needle tip is at approximately one-third the dividing line of the vertebral body in the lateral view of a lumbar X-ray. The contrast is mainly confined around the needle tip and spreads outward and downward along the psoas muscle fibers. In this way, the anterior fascia provides a natural barrier for the ureteropelvic area, and the psoas major muscle provides a natural barrier for the lumbar nerve root. There are several highlights of this article, including 1) a detailed description of the selective CLS procedures, 2) an explanation of the anatomical basis for the implementation of selective CLS, and 3) an explanation of the differences between selective and conventional CLS.

INTRODUCTION:

Chemical lumbar sympathectomy (CLS) has been shown to be an effective treatment for ischemic diseases¹⁻⁵ including thromboangiitis obliterans (sometimes called Buerger's disease), ischemic diabetic foot, Raynaud's disease, paronychia, hyperhidrosis⁶, erythromelalgia⁷⁻⁹, and livedo reticularis¹⁰. It has replaced open surgery due to a number of advantages. It is minimally invasive and economically attractive, it does not require general anesthesia and hospitalization, and it can be performed repeatedly. However, exquisite precision is critical. For example, paraplegia has been reported in CLS using blind technique¹¹. The precision of the procedure is greatly improved with radiographical guidance to control the exact position of the puncture needle tip and puncture path and depth, through the use of contrast media to visualize treatment areas. However, even with radiographical guidance, damages to adjacent organs, particularly ureteropelvic organs¹²⁻¹⁹, have still been reported.

It is commonly practiced to position the needle tip beyond the anterior fascia of the psoas major muscle and inject the drug around the sympathetic trunk^{8,12-15}, which we define as conventional CLS. However, because the location of the sympathetic trunk and ureter are both in front of the anterior fascia, inactivating agents may spread to the ureter and cause damage. In reports of ureteropelvic damage that presented radiographic images¹²⁻¹⁵, the drug was injected in front of the anterior fascia, according to contrast spreading.

Based on our prior experience performing CLS procedures, we have found that targeting gray rami communicantes is more effective and safe compared to targeting the sympathetic trunk. Gray rami communicantes are postganglionic sympathetic fibers located behind the sympathetic trunk and in front of the lumbar nerve root, running along the lateral edge of the vertebral body, mostly within the psoas major muscle. Thus, the anterior fascia provides a good barrier for the ureteropelvic area, and the psoas major muscle provides a good barrier for the lumbar nerve root. We define this procedure as selective CLS, and the technical details of selective CLS are described in this protocol.

PROTOCOL:

The protocol has been approved by the local medical and ethics committees. The procedure lasts approximately 15 minutes per side.

1. Indications

1.1. Ensure the patient has the following indications for CLS: thromboangiitis obliterans (Buerger's disease), ischemic diabetic foot, Raynaud's disease, parmpoplantar hyperhidrosis, erythromelalgia, phantom limb pain, or livedo reticularis of the lower extremities.

2. Contraindications

2.1. Exclude the patient if any of the following contraindications are fulfilled: spinal deformity, bleeding tendency, any infection in the procedure-involved areas, unstable vital signs, pregnancy, or any conditions that render the ability for compliance with the procedure.

3. Preoperative Preparation

3.1. Confirm the presence of indications and lack of contraindications based on clinical and laboratory results.

3.2. Obtain written, informed consent from the patient/relative.

4. Treatment Procedure

4.1. Patient position: ensure that the patient is in lateral decubitus position with the side to be treated facing upwards and the lower limbs flexed to make the back as stretched as possible.

4.2. Disinfection: disinfect the skin at the planned needle puncture site (approximately 30 cm diameter) with 2% povidone iodine, twice. Then, cover the patient's back with surgical towels.

4.3. Anesthetization of the needle tract under lateral fluoroscopy guidance: anesthetize the skin and entire needle tract with 5-8 mL of 0.5% lidocaine (2% lidocaine diluted in 0.9% saline solution) without vasoconstrictors. Advance the needle under local anesthesia to the vertebral body surface gradually. Position the needle tip in the optimal injection area.

NOTE: The puncture point on the skin is approximately 7-8 cm from the dorsomedial line, depending on body shape. **Figure 1A** shows the needle tract. **Figure 1B** shows the optimal injection area, which is at approximately one-third the dividing line of the vertebral body in the lateral view of a lumbar X-ray.

4.4. Confirmation of the accuracy of the needle position with contrast agent: after ensuring that the needle tip is in the optimal area in the lateral view of a lumbar X-ray, inject 0.5 mL of the contrast agent to further evaluate the correct position of the needle tip.

NOTE: The goal is to keep the contrast agent mainly confined to the optimal area then spreading along the psoas major muscle. Distribution of the contrast along the psoas muscle fibers is the marker of successful injection behind the anterior fascia (**Figure 2**).

4.5. Injection of inactivating agent, 5% phenol: after aspiration, to ensure no puncture accidents, inject 2 mL of 5% aqueous solution of phenol into the optimal area (adjust the needle tip direction to ensure 1 mL of phenol spreads to the direction of the head then 1 mL of phenol to the direction of the foot). Then, withdraw the needle from the skin and compress and cover the puncture site with gauze to achieve hemostasis.

NOTE: Steps 4.3 to 4.5 were performed at L3 and L4, respectively.

4.6. Evaluation of the efficacy of sympathetic interruption: define satisfactory sympathetic interruption as a rise of at least 2 °C in skin temperature 5 min after the completion of step 4.5. If satisfactory interruption is not achieved, perform supplemental injection to another optimal area or L5, with a total phenol volume no larger than 10 mL for both sides. Perform the other side in the same manner if needed. Measure the skin temperature using an infrared thermometer, and calculate the average among temperature increases in the shin, plantar, and dorsal foot.

5. Postoperative Care

5.1. Encourage the patient to drink water and ambulate after completion of the procedure. Check the patient on the following day for any discomfort, especially in the loin, groin, and thigh, and for improvement of symptoms and any signs of primary disease. Measure the skin temperature as described in step 4.6. Follow-up with the patient accordingly.

REPRESENTATIVE RESULTS:

The needle tip should be in the optimal area as shown in **Figure 1**. In selective CLS, the contrast is injected behind the anterior fascia of the psoas major muscle, targeting gray rami communicantes. A comparison of contrast spreading in selective CLS (A) and conventional CLS (B) is shown in **Figure 2**.

The expected clinical effects are vasodilation (for treatment of Raynaud's syndrome, livedo reticularis, thromboangiitis obliterans, ischemic diabetic foot, and erythromelalgia; **Figure 3**), sweat reduction (for treatment of hyperhidrosis), and pain relief (for treatment of erythromelalgia and phantom limb pain).

FIGURE LEGENDS:

Figure 1: Relationship between puncture needle and surrounding organs/tissues. (A) A diagram of an axial lumbar CT scan at the level of the needle tract. The white line represents the needle tract. It should be noted that the needle tip reaches close proximity to, but does not break through, the anterior fascia of the psoas muscle (red arc). A = abdominal aorta, V = inferior vena cava. (B) Lateral view of a lumbar X-ray. The green area illustrates the optimal area, located beside the lumbar vessels (usually located in the middle of the vertebral body horizontally), behind the anterior fascia of the psoas muscle and away from the lumbar nerve root behind the vertebral body. This is a safe location, closest to the gray rami communicantes. A = lumbar artery, V = lumbar vein.

Figure 2: Comparison of contrast agent spreading in X-ray views between selective CLS (A) and conventional CLS (B). (A) Selective CLS. The contrast agent was injected behind the anterior fascia of the psoas muscle. The lateral view showed that the contrast agent spread around and behind the needle tip. The anterior-posterior (AP) view showed that the contrast agent diffused outward and downward along the spaces among psoas muscle fibers and formed thin strips, outlining the contour of the muscle fibers. (B) Conventional CLS. The contrast agent was injected in front of the anterior fascia of the psoas muscle. The lateral view showed that the contrast was concentrated in loose tissue in front of the needle tip. The AP view showed that the contrast agent was concentrated along the vertebral body, thus overlapping with the vertebral body in X ray view, and did not diffuse outward.

Figure 3: Clinical observation after selective CLS on the right side of a patient with erythromelalgia. The patient's blood vessels dilated, skin temperature increased, and skin was rosy and dry on the right limb. In contrast, skin was damp and cold with a slight violaceous skin color on the left side without treatment.

Figure 4: Anatomic illustration of sympathetic trunk and gray rami communicantes. (A) Anatomically, the psoas muscle is attached to the lateral side of the vertebral body and the lumbar disc (LD). In this illustration, most of the anterior fascia of the psoas muscle is removed, exposing the psoas muscle. The lumbar sympathetic trunk, located in front of the anterior fascia and adjacent to the abdominal aorta (right lumbar sympathetic trunk adjacent to inferior vena cava, not shown). The enlarged lumbar sympathetic ganglia (SG) are also visible. (B) With the psoas muscle removed from the outside of the vertebral body, the lumbar blood vessels and gray rami communicantes covered in the deep side of the psoas muscle are exposed. The gray rami communicantes originate from the sympathetic ganglia, extend through the anterior fascia, extend backward along the lateral edge of the vertebral body, surround the lumbar blood vessels, and finally join the lumbar nerve roots.

DISCUSSION:

Here we classify CLS as either conventional or selective CLS, with the major difference being the targeting of sympathetic trunk vs. gray rami communicantes (injection of phenol in front of vs. behind the anterior fascia of the psoas major muscle). We have implemented selective CLS in young, female patients with livedo reticularis¹⁰, children with erythromelalgia^{7, 9}, and senile patients with end-stage arteriosclerosis obliterans and high-risk comorbidities, and we have confirmed its long-lasting, beneficial effects and safety.

Ureteropelvic damage is the most frequently reported complication of CLS. There have been more than 10 cases reported¹²⁻¹⁹. In one report, the incidence was reported as 1.24% (3 fibrotic ureter stenoses out of 241 CT-guided CLS)¹⁶, and the author concluded that damage to the ureter may follow even when the procedure is technically satisfactory. Although relatively rare, this complication is serious and causes great harm to the patient. In selective CLS, anterior fascia can provide a natural protective barrier of important organs such as the ureter, abdominal aorta, and inferior vena cava. In our hospital, ureteropelvic damage has never occurred in more than 300 CLS procedures.

The risks of sympathetic trunk inactivation have been recognized in thoracic sympathectomy, and selective sympathicotomy (ramicotomy) has been reported under video-assisted thoroscopic surgery²⁰⁻²². The anatomical distribution of lumbar sympathetic nerves is different from thoracic nerves, which makes implementation of selective CLS possible (see **Figure 4** and explanation below).

The lumbar sympathetic trunk is located in front of the anterior fascia of the psoas muscle, and this location is relatively fixed (**Figure 1, Figure 4**). However, the lumbar sympathetic ganglia have large variations in their relative positions to the vertebral body and in numbers (2-6 in the general population, most commonly 4, maximum of 8) among different individuals. Even within the same individual, distribution of the ganglia is not necessarily symmetrical. In some cases, the ganglia are located beside the vertebral bodies, and in others, they are located beside the lumbar discs. The gray rami communicantes originate from the sympathetic ganglia, and the relative positions to the vertebral body from where they originate are highly variable, too. The relative positions to the vertebral bodies from where communicantes merge into the lumbar nerve roots tend to be consistent, because the locations of lumbar nerve roots are fixed. This makes it possible to target gray rami communicantes without open surgery.

The optimal injection area (**Figure 1**) also successfully avoids the lumbar arteries and veins across the vertebral body, reducing the risk of operative and postoperative bleeding. More importantly, the psoas muscle attached to the lateral side of the vertebral body becomes a natural protective barrier of the lumbar nerve root, protecting the lumbar nerve root behind the psoas muscle and ensuring that no major nerve damage occurs.

There have been no complications other than mild transient genitofemoral neuralgia, which occurred in less than 20% of all cases treated by selected CLS, and all spontaneously resolved within a few days at our hospital. The incidence, intensity, and duration reported in the literature were highly variable, with ranges between 5 and 66%, from mild to significant, and lasting days to years^{2,23-28}. The genitofemoral nerve originates from the L1/L2 segments of the lumbar plexus, then passes downwards and forwards along the psoas muscle and through the anterior fascia of the psoas muscle at approximately the L3 level. Injecting a small amount of drug behind the anterior fascia at L3/L4 would theoretically decrease the chance and degree of genitofemoral nerve damage.

Kuntz's fibers have been blamed for surgical failures of endothoracic sympathectomy²⁹. There are no published reports on Kuntz's fibers in lumbar sympathetic nerve. To ensure satisfactory and persistent sympathetic interruption in CLS, it is recommended to inject the 2 mL of phenol in the optimal area (**Figure 1B**) in the directions of both the head and feet. Moreover, if sympathetic interruption is not satisfactory, it is recommended to inject supplemental phenol to another optimal area or at the L5, which is preferred over injection of a higher dose in the same area. In this regard, the chances of inactivating gray rami communicantes may be highly increased, and a higher degree of safety can be achieved.

Gray rami communicantes are unmyelinated nerves, which are more vulnerable to phenol compared to myelinated nerves. In our experience, 2 mL of 5% phenol is usually sufficient for each injection site. We have used a 4 mL injection in an earlier case, and we gradually lowered the amount to 2 mL.

In summary, we describe the procedure of selective CLS, which targets gray rami communicantes and not the sympathetic trunk, and we emphasize the anterior fascia of the psoas major muscle as a protective barrier when performing selective CLS. The precise needle tract, accurate evaluation of the contrast agent spreading, and multiple injections with small doses of phenol are all critical in ensuring the success of selective CLS.

ACKNOWLEDGMENTS:

This work is funded by grants from Peking University Third Hospital Scientific Research Foundation for the Returned Overseas Scholars (Grant No: 77434-01, Long Zhang) and Beijing Higher Education Young Elite Teacher Project (Grant No: YETP0072, Wen-Hui Wang).

DISCLOSURES:

The authors have nothing to disclose.


REFERENCES:

1. Karanth, V. K., Karanth, T. K., Karanth, L. Lumbar sympathectomy techniques for critical lower limb ischaemia due to non-reconstructable peripheral arterial disease. *Cochrane Database of Systematic Reviews*. **12**, CD011519, doi: 10.1002/14651858, (2016).
2. Kothari, R, Maharaj, A, Tomar, T. S., Agarwal, P., Sharma, D. Percutaneous chemical lumbar sympathectomy for Buerger's disease: Results in 147 patients. *Indian Journal of Vascular Endovascular Surgery*. **4**, 185-190 (2017).
3. Dong, G. X. Chemical lumbar sympathectomy. *Chinese Journal of Practical Surgery*. **4**, 245-246 (2004).
4. Dong, G. X., Zhao, J, Luan, J. Y. Chemical lumbar sympathectomy for the treatment of lower limb ischemia. *Chinese Journal of General Surgery*. **1**, 30-32 (2002).
5. Dong, G. X., Zhao, J. Chemical sympathectomy for ischemia of lower extremity. *Journal of Beijing Medical University*. **1**, 59-60 (1998).
6. Yoshida, W. B., Cataneo, D. C., Bomfim, G. A., Hasimoto, E, Cataneo, A. J. Chemical lumbar sympathectomy in plantar hyperhidrosis. *Clinical Autonomic Research*. **20** (2), 113-115 (2010).
7. Zhang, L, Wang, W. H., Li, L. F., *et al.* Long-term remission of primary erythromelgia with R1150W polymorphism in SCN9A after chemical lumbar sympathectomy. *European Journal of Dermatology*. **20** (6), 763-767 (2010).
8. Cerci, F. B., Kapural, L, Yosipovitch, G. Intractable erythromelgia of the lower extremities successfully treated with lumbar sympathetic block. *Journal of the American Academy of Dermatology*. **69** (5), e270-272 (2013).
9. Wang, W. H., Zhang, L, Dong, G. X., *et al.* Chemical lumbar sympathectomy in the treatment of recalcitrant erythromelgia. *Journal of Vascular Surgery*. **S0741-5214** (18), 31639-2, doi: 10.1016/j.jvs.2018.05.226, (2018).


- 309 10. Wang, W. H., *et al.* Chemical lumbar sympathectomy in the treatment of idiopathic livedo
310 reticularis. *Journal of Vascular Surgery*. **62** (4), 1018-1022 (2015).
- 311 11. Burn, J. M., Langdon, L. Hazard of chemical sympathectomy. *British Medical Journal*. **1**
312 (6120), 1143 (1978).
- 313 12. Wijeyaratne, S. M., Seneviratne, L. N., Umashankar, K., Perera, N. D. Minimal access is not
314 maximal safety: pelviureteric necrosis following percutaneous chemical lumbar
315 sympathectomy. *British Medical Journal Case Reports*. doi: 10.1136/bcr.12.2009.2538,
316 (2010).
- 317 13. Antao, B., Rowlands, T. E., Singh, N. P., McCleary, A. J. Pelviureteric junction disruption as
318 a complication of chemical lumbar sympathectomy. *Cardiovascular Surgery*. **11** (1), 42-44
319 (2003).
- 320 14. Ranjan, P., Kumar, J., Chipde, S. S. Acute renal failure due to bilateral ureteric necrosis
321 following percutaneous chemical lumbar sympathectomy. *Indian Journal of Nephrology*.
322 **22** (4), 292-294 (2012).
- 323 15. Cutts, S., Williams, H. T., Lee, J., Downing, R. Ureteric injury as a complication of chemical
324 sympathectomy. *European Journal of Vascular and Endovascular Surgery*. **19** (2), 212-213
325 (2000).
- 326 16. Ernst, S., Heindel, W., Fischbach, R., *et al.* Complications of CT guided lumbar
327 sympathectomy: our own experiences and literature review. *Rofo*. **168** (1), 77-83 (1998).
- 328 17. Daschner, H., Allgayer, B. Ureteral obstruction following CT-guided lumbar sympathetic
329 exclusion. *Rofo*. **161**, 85-87 (1994).
- 330 18. Rytto, N., Boe, S., Nielsen, H., Jacobsen, J. Necrosis of ureter as a complication to
331 chemical lumbar sympathectomy. Report of a case. *Acta Chirurgica Scandinavica*. **147** (1),
332 79-80 (1981).
- 333 19. Benckroun, A., Lachkar, A., Soumana, A., *et al.* Ureter injuries. Apropos of 42 cases.
334 *Annals of Urology*. **31** (5), 267-272 (1997).
- 335 20. Coveliers, H., Meyer, M., Gharagozloo, F., *et al.* Robotic selective postganglionic thoracic
336 sympathectomy for the treatment of hyperhidrosis. *Annals of Thoracic Surgery*. **95** (1),
337 269-274 (2013).
- 338 21. Coveliers, H., Meyer, M., Gharagozloo, F., Wisselink, W. Selective sympathectomy for
339 hyperhidrosis: technique of robotic transthoracic selective postganglionic efferent
340 sympathectomy. *European Journal of Cardio-thoracic Surgery*. **43** (2), 428-430 (2013).
- 341 22. Akil, A., Semik, M., Fischer, S. Efficacy of Miniuniportal Video-Assisted Thoracoscopic
342 Selective Sympathectomy (Ramicotomy) for the Treatment of Severe Palmar and Axillar
343 Hyperhidrosis. *Thoracic Cardiovascular Surgery*. doi: 10.1055/s-0038-1642030, (2018).
- 344 23. Sanderson, C. J. Chemical lumbar sympathectomy with radiological assessment. *Annals of*
345 *the Royal College Surgeons of England*. **63** (6), 420-422 (1981).
- 346 24. Lee, K. S., Su, Y. F., Lieu, A. S., *et al.* The outcome of percutaneous computed tomography-
347 guided chemical lumbar sympathectomy for patients with causalgia after lumbar
348 discectomy. *Surgical Neurology*. **69** (3), 274-280 (2008).
- 349 25. Reid, W., Watt, J. K., Gray, T. G. Phenol injection of the sympathetic chain. *British Journal*
350 *of Surgery*. **57** (1), 45-50 (1970).

- 351 26. Haynsworth, R. F. Jr, Noe, C. E. Percutaneous lumbar sympathectomy: a comparison of
352 radiofrequency denervation versus phenol neurolysis. *Anesthesiology*. **74** (3), 459-463
353 (1991).
- 354 27. Boas, R. A. Sympathetic blocks in clinical practice. *International Anesthesiology Clinics*. **16**
355 (4), 149-182 (1978).
- 356 28. Duncan, J. A. Chemical lumbar sympathectomy. *Journal of Bone and Joint Surgery*. **67** (2),
357 174-175 (1985).
- 358 29. Marhold, F., Izay, B., Zacherl, J., Tschabitscher, M., Neumayer, C. Thoracoscopic and
359 anatomic landmarks of Kuntz's nerve: implications for sympathetic surgery. *Annals of*
360 *Thoracic Surgery*. **86** (5), 1653-1658 (2008).
- 361


A: needle tract



B: optimal area (green)



A: selective CLS



B: conventional CLS




Figure 3


[Click here to access/download;Figure;photo3.jpg](#)



A: sympathetic trunk



B: gray rami communicantes



Name of Material/ Equipment	Company	Catalog Number
0.9% Saline solution	Chinese Dazhong Pharmaceutical Co.,Ltd.	8F84D7
10-cm 9# puncture needle	Peking University Third Hospital	Not Applicable
2% Lidocaine Hydrochloride Injection solution	Hubei Tiansheng Pharmaceutical Co.,Ltd.	20180434
5% Phenol diluted in aqueous solution	Peking University Third Hospital	Not Applicable
Angiography system (DSA)	Philips	FD20
Aseptic puncture kit	Peking University Third Hospital	Not Applicable
Contrast media (iodixanol injection; 320)	GE Healthcare	14160155
Infrared frontal thermometer	OMRON health care (China) Co.,Ltd.	MC-720
Iodophors skin disinfectants	Shanghai Likang Disinfectant Hi-Tech Co., Ltd.	20180404
Sterile surgical gloves	Beijing Ruijing Latex products Co., Ltd.	2018070352
Syringes and needles 10 mL	Shandong Weigao Group Medical Polymer Co.,Ltd.	20180711
Syringes and needles 5 mL	Shandong Weigao Group Medical Polymer Co.,Ltd.	20180721

Comments/Description
10 mL x 2
7# for children
5 mL x 2
10 mL
have X-ray fluoroscopy function
6 pieces of surgical towel, gauze, cotton balls, blood vessel forceps, etc.
320 mg I/mL
10 mL x 2
5 mL x 1



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article: Targeting gray rami communicantes, not sympathetic trunk, in selective chemical lumbar sympathectomy

Author(s): Wen-Hui Wang, Long Zhang, Guo-Xiang Dong, Xuan Li

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's


expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:	Long Zhang	
Department:	Department of Interventional Radiology and Vascular Surgery,	
Institution:	Peking University Third Hospital, Beijing, China	
Article Title:	Targeting gray rami communicantes, not sympathetic trunk, in selective chemical lumbar sympathectomy	
Signature:		Date: July 29, 2018

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Editorial comments and responses:

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.

Answer: The manuscript is thoroughly proofread.

2. Please include an ethics statement before the numbered protocol steps, indicating that the protocol follows the guidelines of your institution's human research ethics committee.

Answer: The ethics statement is transferred before the numbered protocol steps.

3. Unfortunately, there are a few sections of the manuscript that show significant overlap with previously published work. Though there may be a limited number of ways to describe a technique, please use original language throughout the manuscript. Please check the iThenticateReport attached to this email.

Answer: We revised the manuscript according to the iThenticateReport. The revised parts are in red color.

4. Please split some long steps so that each step contains 2-3 actions and is less than 4 lines.

Answer: The long steps are revised. The notes are transferred before the numbered protocol steps.

5. Please remove all headers from Representative Results. Please avoid sectioning Representative Results.

Answer: The headers of Representative Results are removed. The Representative Results are not sectioned now.

6. Please use standard SI unit symbols and prefixes such as μL , mL, L, g, m, etc.

Answer: The standard SI unit symbols and prefixes are used, e.g. ml are replaced by mL.

7. Please ensure that the references appear as the following:

Lastname, F.I., LastName, F.I., LastName, F.I. Article Title. *Source*. **Volume** (Issue), FirstPage – LastPage, (YEAR).

For more than 6 authors, list only the first author then *et al*.

Answer: The references are revised accordingly. Some of them don't have page number, so we put doi number there.